Driving research of Myalgic Encephalomyelitis / Chronic Fatigue Syndrome (ME / CFS),
Post Treatment Lyme Disease Syndrome (PTLDS), Fibromyalgia and Long Covid

OMF-finansiert Studie for å Rød blodcelledeformabilitetsstudie – utdrag

Vi er veldig glade for fortelle at OMF-finansiert forskningRød blodcelle deformasjon Av Mohsen Nemat-Gorgani, PhD fra Stanford University, og Anand Ramasubramanian, PhD fra San Jose State University I samarbeid med Ron Davis, PhD, og deres samarbeidsteam, nettop har blitt antatt i Blood Journal og blitt akseptert for publisering I Clinical Hemorheology og microcirculation. Denne viktige forskningen kan lede til en potensiell biomarkør og diagnostisk test.

Denne kritiske studien har vært fullfinansiert av Open Medicine Foundation (OMF) gjennom donasjoner fra våre generøse givere. Les gjerne oppsummeringen fra Dr. Ron Davis og abstraktet nedenfor. Sammen dekker vi stadig nytt landskap og kommer nærmere svar.

Oppsummering skrevet av Ronald W. Davis, PhD

Dette paperet dokumenterer at røde blodceller har mindre formbarhet i pasienter med ME / CFS sammenlignet med friske controller. Dette kan potensielt være en biomarkør, og vi går videre til å designe nye verktøy som kan vise en klar distinksjon mellom pasienter og friske kontroller. Disse verktøyene vil være håndholdte og enkle å bruke av leger på deres legekontor, eller ved klinisk testing i laboratorier. Tidligere arbeid har primært sett på formen til røde blodceller, noes om er vanskelig å kvantifisere. Vår tilnærming vil gi en klar kvantitative tall. Det måler evnen til røde blodlegemer til deformert. Vår tilnærming vil skape et tydelig måltall. Det måler røde blodcellers evne til å deformere seg selv for å klemme seg inn I kapillærer, en egenskap røde blodceller må ha for en sunn blodgjennomstrømming. Vi måler hundrevis av celler fra hver pasient, så på grunn av dette får vi en statistisk signifikant distinksjon mellom pasienter og sunne kontroller selv om vi har et lavt antall pasienter. Vi setter I gang med å utvikle disse nye verktøyene så raskt som mulig.

Deformabilitet I erythrocytter som en potensiell biomarkør for Kronisk trøtthet syndrom (Blood Journal, Nov 2018:

Forfattere: Amit K. Saha, Brendan R. Schmidt, Julie Wilhelmsen, Du Nguyen, Justin Av, Vineeth C. Skitne, Mohsen Nemat-Gorgani, Anand K. Ramasubramanian Og Ronald W. Davis

“Våre data viser at en signifikant lavere deformabilitet hos RBC fra ME / CFS-pasienter kan ha bakgrunn I oksidativt stress, og antyder at endringer I mikrovaskulær perfusjon kan være en mulig årsak for ME / CFS-symptomer. Våre data viser også at RBC deformabilitet kan virke som en potensiall biomarkør for ME / CFS, selv om videre studier trengs for non-spesifikk klassifisering av sykdommen. 

Les originalutgivelsen på Blood Journal 

Takk til Siri for denne oversettelsen.

 

Myalgic Encephalomyelitis / Chronic Fatigue Syndrome (ME / CFS) Post Treatment Lyme Disease Syndrome (PTLDS), Fibromyalgia Leading Research. Delivering Hope.Open Medicine Foundation®

Averting a second pandemic:

Open Medicine Foundation leads groundbreaking international study of

Long COVID’s conversion to ME/CFS

AGOURA HILLS, CALIF.  — Open Medicine Foundation (OMF) is leading a large-scale international collaborative study investigating the potential conversion of Post-Acute Sequelae SARS-CoV-2 infection — more commonly known as Long COVID or Post-COVID Syndrome —  to Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS), a chronic, life-altering disease with no known cause, diagnostic test or FDA approved treatments available.

Up to 2.5 million people in the U.S. alone suffer from ME/CFS; the COVID-19 pandemic could at least double that number. An estimated 35 percent of Americans who had COVID-19 have failed to fully recover several months after infection, prompting many to call it “a potential second pandemic.”

OMF recognized a familiar health crisis emerging, one with eerie similarities to ME/CFS. This crisis presented a unique opportunity to understand how a viral infection — in this case COVID-19 — may develop into ME/CFS in some patients. The goal is to find targeted treatments for ME/CFS patients and ultimately prevent its onset in people infected with SARS-CoV-2 or other infections.

The federal government is only now investing in Post-COVID research, with no focus on its connection to ME/CFS. OMF has already engaged researchers for the largest-scale study of its kind, solely supported by private donors who have contributed over one million dollars to date. When fully funded, the five million dollar, three-year study will be conducted across the globe at OMF funded Collaborative Research Centers, led by some of the world’s top researchers and ME/CFS experts.

BACKGROUND

In a significant percentage of patients, infections preceded their development of ME/CFS.  For example, according to the CDC about one in ten infected with Epstein-Barr virus, Ross River virus, or Coxiella burnetti develop symptoms that meet the criteria for ME/CFS.

THE STUDY

The ability to follow the development of ME/CFS from a known viral infection is unprecedented to date and crucial to researchers’ understanding of the disease. The focus of this study is to find the biological differences between persons returning to good health after COVID-19 and persons who remained ill more than six months after infection and developed ME/CFS.  Understanding these alterations in key pathways can lead to groundbreaking discoveries including new biomarkers, drug targets, and prevention and treatment strategies.

###

About Open Medicine Foundation

Established in 2012, Open Medicine Foundation leads the largest, concerted worldwide nonprofit effort to diagnose, treat, and prevent ME/CFS and related chronic, complex diseases such as Post Treatment Lyme Disease Syndrome, Fibromyalgia, and Post COVID. OMF adds urgency to the search for answers by driving transformational philanthropy into global research. We have raised over $28 Million from private donors and facilitated and funded the establishment of six prestigious ME/CFS Collaborative Research Centers around the world. To learn more, visit www.omf.ngo.

CONTACT:

Heather Ah San

Development and Communications Manager

1-650-242-8669

heather@omf.ngo